A real-world study focused on the long-term efficacy of mycophenolate mofetil as first-line treatment of autoimmune hepatitis
Auteur
Zachou K., Gatselis N.K., Arvaniti P., Gabeta S., Rigopoulou E.I., Koukoulis G.K., Dalekos G.N.Date
2016Language
en
Sujet
Résumé
Background Front-line therapy with mycophenolate mofetil (MMF) in autoimmune hepatitis (AIH) has shown high on-treatment remission rates. Aim To study prospectively in a real-world fashion the long-term outcome of a large group of consecutive treatment-naïve AIH patients. Methods Between 2000 and 2014, 158 patients were recruited but only 131 were eligible for treatment (109 MMF/prednisolone; 22 prednisolone ± azathioprine). Long-term data on outcome after drug withdrawal were evaluated. Patients stopped treatment after having achieved complete response (normal transaminases and IgG) for at least the last 2 years. Results At diagnosis, 31.6% of patients had cirrhosis and 72.8% insidious presentation. A total of 102 of 109 (93.6%) responded initially to MMF within 2 (1-18) months. A total of 78 of 109 (71.6%) had complete response on treatment and 61 of 78 (78.2%) maintained remission off prednisolone. MMF-treated patients had increased probability of complete response compared to those receiving azathioprine (P = 0.03). Independent predictors of complete response were lower ALT at 6 months (P = 0.001) and acute presentation (P = 0.03). So far, treatment withdrawal was feasible in 40/109 patients and 30 (75%) are still in remission after 24 (2-129) months. Remission maintenance was associated with longer MMF treatment (P = 0.005), higher baseline ALT (P < 0.02), lower IgG on 6 months (P = 0.004) and histological improvement. Conclusions Mycophenolate mofetil proved to be an efficient first-line treatment for AIH, achieving so far the highest rates of remission maintenance off treatment (75%) ever published for at least a median of 2 years, although the remission criteria used were strict. However, the risk of potential bias and overestimation of intervention benefits from MMF cannot be completely excluded as this is a real world and not a randomised controlled trial. © 2016 John Wiley & Sons Ltd.
Collections
Related items
Showing items related by title, author, creator and subject.
-
Increased primary autoimmune thyroid diseases and thyroid antibodies in sarcoidosis: Evidence for an under-recognised extrathoracic involvement in sarcoido
Malli, F.; Bargiota, A.; Theodoridou, K.; Florou, Z.; Bardaka, F.; Koukoulis, G. N.; Gourgoulianis, K. I.; Daniil, Z. (2012)Objective and Design: Sarcoidosis has been associated with thyroid diseases. However, until today no definite conclusions have been drawn. We aimed to assess the frequency of thyroid disorders and the levels of thyroid ... -
Decreased serum DNase1-activity in patients with autoimmune liver diseases
Gatselis N.K., Vakrakou A.G., Zachou K., Androutsakos T., Azariadis K., Hatzis G., Manoussakis M.N., Dalekos G.N. (2017)Deoxyribonuclease1 (DNase1) is involved in chromatin degradation of apoptotic cells. Its deficiency results in accumulation of self-DNA, which in turn may induce inflammation and autoimmunity. We assessed for the first ... -
First Results From a Propensity Matching Trial of Mycophenolate Mofetil vs. Azathioprine in Treatment-Naive AIH Patients
Dalekos G.N., Arvaniti P., Gatselis N.K., Samakidou A., Gabeta S., Rigopoulou E., Koukoulis G.K., Zachou K. (2022)Background/Aims: As previous real-world studies and meta-analyses have shown that mycophenolate mofetil (MMF) might have better efficacy than azathioprine (AZA) in autoimmune hepatitis (AIH), we conducted a propensity ...